Tesetaxel - Odonate Therapeutics

Drug Profile

Tesetaxel - Odonate Therapeutics

Alternative Names: DJ-927

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Pharmaceutical
  • Developer Genta (CEASED); Odonate Therapeutics
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Discontinued Bladder cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Prostate cancer; Solid tumours

Most Recent Events

  • 01 Dec 2017 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03326674)
  • 07 Nov 2017 Odonate Therapeutics plans the phase III CONTESSA trial for Breast cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in December 2017 (NCT03326674)
  • 07 Nov 2017 Discontinued - Phase-I for Solid tumours (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top